Equities research analysts expect that Myriad Genetics, Inc. (NASDAQ:MYGN) will post sales of $193.54 million for the current quarter, according to Zacks. Five analysts have provided estimates for Myriad Genetics’ earnings. The highest sales estimate is $194.28 million and the lowest is $193 million. Myriad Genetics posted sales of $186.5 million during the same quarter last year, which suggests a positive year over year growth rate of 3.8%. The company is scheduled to report its next quarterly earnings results on Tuesday, August 8th.

According to Zacks, analysts expect that Myriad Genetics will report full-year sales of $193.54 million for the current year, with estimates ranging from $756.2 million to $768.13 million. For the next year, analysts anticipate that the firm will report sales of $790.82 million per share, with estimates ranging from $770.91 million to $848 million. Zacks’ sales calculations are a mean average based on a survey of analysts that cover Myriad Genetics.

Myriad Genetics (NASDAQ:MYGN) last announced its earnings results on Tuesday, May 2nd. The company reported $0.27 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.24 by $0.03. Myriad Genetics had a return on equity of 12.02% and a net margin of 8.08%. The business had revenue of $196.90 million for the quarter, compared to analyst estimates of $188.89 million.

MYGN has been the subject of several analyst reports. Ladenburg Thalmann Financial Services raised Myriad Genetics from a “sell” rating to a “neutral” rating in a research note on Wednesday, February 8th. Cowen and Company reissued a “market perform” rating and issued a $19.00 price objective on shares of Myriad Genetics in a research note on Tuesday, March 28th. Jefferies Group LLC reissued a “hold” rating and issued a $21.00 price objective (up from $18.00) on shares of Myriad Genetics in a research note on Wednesday, May 3rd. Zacks Investment Research raised Myriad Genetics from a “sell” rating to a “hold” rating in a research note on Wednesday, February 1st. Finally, Piper Jaffray Companies reissued a “neutral” rating and issued a $21.00 price objective on shares of Myriad Genetics in a research note on Tuesday, February 7th. Three research analysts have rated the stock with a sell rating, nine have issued a hold rating and one has given a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $23.00.

In other Myriad Genetics news, Director John T. Henderson purchased 6,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 23rd. The stock was bought at an average cost of $18.66 per share, with a total value of $111,960.00. Following the completion of the transaction, the director now owns 38,524 shares of the company’s stock, valued at approximately $718,857.84. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 6.20% of the company’s stock.

Several hedge funds have recently modified their holdings of the stock. Scopia Capital Management LP acquired a new stake in shares of Myriad Genetics during the third quarter worth approximately $75,316,000. Norges Bank acquired a new stake in shares of Myriad Genetics during the fourth quarter worth approximately $14,319,000. BlackRock Advisors LLC increased its stake in shares of Myriad Genetics by 0.6% in the third quarter. BlackRock Advisors LLC now owns 137,450 shares of the company’s stock worth $2,829,000 after buying an additional 803 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Myriad Genetics by 14.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,654,854 shares of the company’s stock worth $27,587,000 after buying an additional 204,049 shares during the last quarter. Finally, Comerica Bank increased its stake in shares of Myriad Genetics by 4.8% in the fourth quarter. Comerica Bank now owns 51,750 shares of the company’s stock worth $845,000 after buying an additional 2,348 shares during the last quarter.

WARNING: This piece of content was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of international trademark and copyright laws. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/05/11/193-54-million-in-sales-expected-for-myriad-genetics-inc-mygn-this-quarter.html.

Shares of Myriad Genetics (NASDAQ:MYGN) traded down 2.64% during midday trading on Thursday, reaching $22.12. The company had a trading volume of 432,322 shares. Myriad Genetics has a 12-month low of $15.15 and a 12-month high of $35.51. The stock’s 50 day moving average is $19.11 and its 200-day moving average is $17.92. The stock has a market capitalization of $1.51 billion, a PE ratio of 47.26 and a beta of 0.26.

About Myriad Genetics

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

5 Day Chart for NASDAQ:MYGN

Get a free copy of the Zacks research report on Myriad Genetics (MYGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.